Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators

Addiction Biology

Volumn 14, Issue 3, 2009, Pages 328-337

  Ooteman, Wendy ^a,b,c   Naassila, Mickaël ^d   Koeter, Maarten W J ^b   Verheul, Roel ^b,e   Schippers, Gerard M ^b   Houchi, Hakim ^d   Daoust, Martine ^d   Van Den Brink, Wim ^b  

^a San Francisco Coordinating Center   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^e Viersprong Institute for Studies on Personality Disorders VISPD   (Netherlands)

Author keywords

Acamprosate; Alcoholism; Genotype; Matching; Naltrexone; Pharmacogenomics

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ACAMPROSATE; DOPAMINE RECEPTOR; GLUTAMATE RECEPTOR; NALTREXONE; OPIATE RECEPTOR;

ADULT; ALCOHOLISM; ARTICLE; ASSOCIATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG EFFECT; EXPOSURE; FEMALE; GENETIC POLYMORPHISM; GENETIC TRAIT; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REINFORCEMENT; WITHDRAWAL SYNDROME;

ADULT; ALCOHOL DETERRENTS; ALCOHOLISM; CUES; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MOTIVATION; NALTREXONE; NARCOTIC ANTAGONISTS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE D2; RECEPTORS, GABA-A; RECEPTORS, OPIOID, MU; TAURINE; TREATMENT OUTCOME;

EID: 67650477063     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/j.1369-1600.2009.00159.x     Document Type: Article

References (27)

1. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington DC : American Psychiatric Association.
2. Anton RF, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H, Goldman D (2008) An evaluation of mu-opioid receptor (oprm1) as a predictor of naltrexone response in the treatment of Alcohol Dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 65 : 135 144. (Pubitemid 351222547)
3. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L (1998) Single-nucleotide polymorphism in the human μ-opioid receptor gene alters beta-endorphin binding and activity, possible implications for opiate addiction. Proc Natl Acad Sci USA 95 : 9608 9613. (Pubitemid 28506279)
4. Cooney NL, Litt MD, Morse PA, Bauer LO, Gaupp L (1997) Alcohol cue reactivity, negative-mood reactivity, and relapse in treated alcoholic men. J Abnorm Psychol 106 : 243 250. (Pubitemid 27184745)
5. Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, Krystal JH, VA Cooperative Study #425 Study Group (2007) Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res 31 : 555 563. (Pubitemid 46434892)
6. Gottesman II, Gould TD (2003) The endophenotype concept in psychiatry, etymology and strategic intentions. Am J Psychiatry 160 : 636 645. (Pubitemid 41079594)
7. Kiefer F, Jahn H, Wiedemann K (2005) A neuroendocrinological hypothesis on gender effects of naltrexone in relaopse prevention treatment. Pharmacopsychiatry 38 : 184 186. (Pubitemid 41059228)
8. Kim SG, Kim CM, Choi SW, Jae YM, Lee HG, Son BK, Kim JG, Choi YS, Kim HO, Kim SY, Oslin DW (2009) A mu opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacology (Berl) 201 : 611 618.
9. Koob GF, Le Moal M (2006) Neurobiology of Addiction. London, UK : Elsevier Inc. Academic Press.
10. McGeary JE, Monti PM, Rohsenow DJ, Tidey J, Swift R, Miranda R Jr. 2006) Genetic moderators of naltrexone's effects on alcohol cue reactivity. Alcohol Clin Exp Res 30 : 1288 1296. (Pubitemid 44114679)
11. Mann K (2004) Pharmacotherapy of alcohol dependence, a review of the clinical data. CNS Drugs 18 : 485 504. (Pubitemid 38829945)
12. Mann K, Lehert P, Morgan MY (2004) The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals, results of a meta-analysis. Alcohol Clin Exp Res 28 : 51 63. (Pubitemid 38114023)
13. Monti PM, Rohsenow DJ, Rubonis AV, Niaura RS, Sirota AD, Colby SM, Goddard P, Abrams DB (1993a) Cue exposure with coping skills treatment for male alcoholics, a preliminary investigation. J Consult Clin Psychol 61 : 1011 1019. (Pubitemid 24006591)
14. Monti PM, Rohsenow DJ, Rubonis AV, Niaura RS, Sirota AD, Colby SM, Abrams DB (1993b) Alcohol cue reactivity, effects of detoxification and extended exposure. J Stud Alcohol 54 : 235 245. (Pubitemid 23101830)
15. Ooteman W (2006) Psychobiological pathways to alcohol craving and their relevance for patient treatment matching. Thesis, Febodruk, Enschede, The Netherlands.
16. Ooteman W, Koeter MWJ, Verheul R, Schippers GM, Van den Brink W (2006) Measuring craving, an attempt to connect subjective craving with cue reactivity. Alcohol Clin Exp Res 30 : 57 69. (Pubitemid 43341397)
17. Ooteman W, Koeter MWJ, Verheul R, Schippers GM, Van den Brink W (2007) The effect of naltrexone and acamprosate on cue-induced craving and physiological cue reactivity in alcoholics. Eur Neuropsychopharmacol 17 : 558 566.
18. Ooteman W, Verheul R, Naassila M, Daoust M, Schippers GM, Koeter MWJ, Van den Brink W (2005) Patient-treatment matching with anti-craving medications in alcohol-dependent patients, A review on phenotypic, endophenotic and genetic indicators. J Subst Use 10 : 75 96. (Pubitemid 40691316)
19. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, O'Brien CP (2003) A functional polymorphism of the μ-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28 : 1546 1552. (Pubitemid 41070891)
20. Ray LA, Hutchison KE (2004) A polymorphism of the μ-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res 28 : 1789 1795. (Pubitemid 39665194)
21. Ritchie T, Noble EP (1996) [3H]naloxone binding in the human brain, alcoholism and the TaqI A D2 dopamine receptor polymorphism. Brain Res 718 : 193 197. (Pubitemid 26168742)
22. Rohsenow DJ, Monti PM (1999) Does urge to drink predict relapse after treatment? Alcohol Res Health 23 : 225 232.
23. Roozen HG, De Waart R, Van der Windt DA, Van den Brink W, De Jong CA, Kerkhof AJ (2006) A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence. Eur Neuropsychopharmacol 16 : 311 323. (Pubitemid 43898671)
24. Rubonis AV, Colby SM, Monti PM, Rohsenow DJ, Gulliver SB, Sirota AD (1994) Alcohol cue reactivity and mood induction in male and female alcoholics. J Stud Alcohol 55 : 487 494. (Pubitemid 24191420)
25. Srisurapanont M, Jarusuraisin N (2005a) Opioid antagonists for alcohol dependence. Cochrane Database Syst. Rev. 25, CD001867.
26. Srisurapanont M, Jarusuraisin N (2005b) Naltrexone for the treatment of alcoholism, a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 8 : 267 280. (Pubitemid 40769268)
27. Verheul R, Van den Brink W, Geerlings P (1999) A three-pathway psychobiological model of craving for alcohol. Alcohol Alcohol 34 : 197 222. (Pubitemid 29213715)